Piomic Medical AG, a Swiss ETH Zurich start-up and an emerging regenerative medtech company focused on deep tissue regeneration through physical stimulation therapies, raised USD 25 million in growth equity. Swisscanto (CH) Private Equity Switzerland Growth II L-QIF KmGK ("Swisscanto"), the growth fund of Zürcher Kantonalbank's asset management division, led the financing round with a CHF 10 million commitment.

The Schellenberg Wittmer team consisted of Christoph Vonlanthen (Partner, overall lead), Christophe Granata Goldman, Gregory Marcos and Sven Riva (Corporate / M&A), Stéphanie Chuffart-Finsterwald and Nathan Matantu (IP / Life Sciences), as well as Sara Rousselle-Ruffieux and Elio Correia Fonseca (Employment).